Description: Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna in 2017 and is headquartered in Boston, MA
Home Page: www.akouos.com
AKUS Technical Analysis
645 Summer Street
Boston,
MA
02210
United States
Phone:
857 410 1818
Officers
| Name | Title |
|---|---|
| Dr. Emmanuel Simons M.B.A., Ph.D. | Co- Founder, Pres, CEO & Director |
| Dr. Michael John McKenna M.D. | Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board |
| Ms. Jennifer Anne Wellman M.S. | Chief Operating Officer |
| Dr. Luk H. Vandenberghe M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. William F. Sewell Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Richard Smith M.D. | Founder & Member of Scientific Advisory Board |
| Ms. Sachiyo Minegishi | CFO, Treasurer, Assistant Sec. & Principal Accounting Officer |
| Ms. Stacy Price | Chief Technical Officer |
| Dr. Aaron Tward M.D., Ph.D. | Chief Scientific Officer |
| Dr. Karoline K. Shair | Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7152 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-06-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |